



PO Box 12050 | Austin, TX 78711 | 800-252-7031 | tdi.texas.gov/wc

To: Texas Workers' Compensation System Participants

From: Graves Owen, M.D., Medical Advisor

Date: October 18, 2023

Re: Input needed for developing the Gabapentin or Pregabalin with Opioids Plan-Based Audit

The Texas Department of Insurance, Division of Workers' Compensation (DWC) seeks input for the Gabapentin or Pregabalin with Opioids Plan-Based Audit. The audit will evaluate the appropriateness of a health care practitioner's decision making and recordkeeping that support the use and effectiveness when prescribing gabapentin or pregabalin in combination with an opioid. The audit sets the scope, methodology, and selection standards laid out in the Medical Quality Review Process (Process).

The medical advisor approved Gabapentin or Pregabalin with Opioids as part of the Calendar Year 2023 Medical Quality Review Annual Audit Plan (Annual Audit). Information about the Process, Annual Audit, and the proposed Gabapentin or Pregabalin with Opioids Plan-Based Audit is on the TDI website at <https://www.tdi.texas.gov/wc/hcprovider/medadvisor.html>.

You can email suggestions for this proposed Gabapentin or Pregabalin with Opioids Plan-Based Audit to OMA@tdi.texas.gov. The deadline to email your suggestions is 5 p.m., Central time, on October 31, 2023.

If you have any questions, contact Chichi Onoriobe at Chichi.Onoriobe@tdi.texas.gov or 512-804-4805.